Norris Medicines Ltd
NSE: BSE: 524414
₹13.50
(5.80%)
Sun, 24 May 2026, 04:12 pm
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KNorris Medicines Analysis
dividend
- Unable to evaluate Norris Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Norris Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Norris Medicines's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- Norris Medicines has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Norris Medicines's long term commitments exceed its cash and other short term assets.
- Irrelevant to check if Norris Medicines's debt level has increased considering it has negative shareholder equity.
- Norris Medicines has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
- The tenure for the Norris Medicines board of directors is about average.
- Vimal's remuneration is lower than average for companies of similar size in India.
- Vimal's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Norris Medicines management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Norris Medicines is not covered by any analysts.
past
- Unable to compare Norris Medicines's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Norris Medicines does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Norris Medicines has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Norris Medicines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Norris Medicines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Norris Medicines's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- BSE:524414 is up 6.1% along with the Pharmaceuticals industry (6.8%) over the past month.
- Norris Medicines has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Norris Medicines is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Norris Medicines is loss making, we can't compare the value of its earnings to the India market.
- 524414 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524414 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524414 is up 6.1% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800